Developed by Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical, this product is currently commercialized in the USA and Canada by Taiho Oncology and Taiho Pharma Canada, Inc. Taiho ...

H.C. Wainwright adjusted its outlook on Cullinan Oncology Inc. (NASDAQ:CGEM), raising the price target to $33.00 from the previous $28.00 while maintaining a Buy rating on the company's shares.

Taiho Pharmaceutical and Taiho Oncology reported that a Phase 1/2 study of the drug zipalertinib met its primary endpoint of overall response rate in a study of EGFR lung cancer patients. The drug was ...